Benjamin Movsas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Benjamin Movsas has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
H. Choy
5 shared publicationsJ. Owen
ACR Clinical Research Center, Philadelphia, PA
4 shared publicationsR. Komaki
M. D. Anderson Cancer Center, Houston, TX
4 shared publicationsC. Langer
University of Pennsylvania Hospital, Philadelphia, PA
3 shared publications- Feng-Ming Kong
Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
3 shared publications Radiation Therapy Oncology Group
3 shared publications
Latest Publications
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93  (3) , S110
Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93  (3) , S110
Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825
- Open Access
- 1 October 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81  (2) , S575
Co-morbidities Affect Cancer Treatment Strategies And Outcome In Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC): Report Of Quality Research In Radiation Oncology (QRRO) Data For Stage III NSCLC Patients
- 1 October 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81  (2) , S575
Open AccessCo-morbidities Affect Cancer Treatment Strategies And Outcome In Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC): Report Of Quality Research In Radiation Oncology (QRRO) Data For Stage III NSCLC Patients
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29  (15) , 6061
Prognostic significance of QOL deterioration during early lung cancer survivorship: Secondary analysis of RTOG 0212 and 0214.
6061 Background: We assessed the association of deterioration (D) in patient-reported quality of life (QOL) with survival following curative-intent treatment for limited-disease small cell lung cancer (LD-SCLC) and locally advanced non-small cell lung cancer (LA-NSCLC). Methods: Patients with LD-SCLC and LA-NSCLC were enrolled on RTOG trials 0212 and 0214, respectively. QOL was assessed as a secondary endpoint using EORTC QLQ-C30 and BN20 at baseline (following locoregional therapy but before PCI or observation) and at 6 and 12 months (mos) follow-up. D was defined compared to baseline using the reliable change index method and correlated with overall survival and the cumulative incidence of brain and distant metastases using the Cox proportional hazards and Fine and Gray’s proportional hazards models, respectively. Covariates included age, gender, race, partner status, education, Zubrod performance score, histology, PCI use, and PCI dose. Results: 552 (91%) of the 604 eligible patients accrued to RTOG 0212 and RTOG 0214 had baseline QOL assessments and were included in this pooled analysis. Compliance with QOL assessments (66% at 6 mos and 54% at 12 mos) did not differ between RTOG 0212 and 0214. After adjusting for baseline QOL score and covariates, D in global health status/QOL at 6 and 12 mos, fatigue at 6 and 12 months, and cognitive functioning at 12 months was associated with worse overall survival, compared to no deterioration/improvement (ND) (Table). D in global health status/QOL (1.82, 1.28-2.59, p=0.0009) and fatigue (1.61, 1.15-2.27, p=0.006) at 6 months was also associated with increased risk of distant metastasis. Conclusions: Longitudinal deterioration in global health status/QOL, fatigue and cognitive functioning at 6 and 12 months after definitive treatment for LD-SCLC or LA-NSCLC is potentially an early surrogate marker for poor overall survival. Global Health Status/QOL Fatigue Cognitive functioning 6 mos 12 mos 6 mos 12 mos 12 mos D ND D ND D ND D ND D ND Median survival (mos) 21.4 37.2 30.0 38.6 27.4 33.0 33.0 42.7 28.5 49.0 Adjusted hazard ratio 2.41 2.22 1.71 1.87 1.88 95% confidence interval 1.70-3.43 1.39-3.56 1.20-2.43 1.15-3.04 1.18-3.00 P <0.0001 0.0009 0.003 0.01 0.008
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29  (15) , 6061
Prognostic significance of QOL deterioration during early lung cancer survivorship: Secondary analysis of RTOG 0212 and 0214.
6061 Background: We assessed the association of deterioration (D) in patient-reported quality of life (QOL) with survival following curative-intent treatment for limited-disease small cell lung cancer (LD-SCLC) and locally advanced non-small cell lung cancer (LA-NSCLC). Methods: Patients with LD-SCLC and LA-NSCLC were enrolled on RTOG trials 0212 and 0214, respectively. QOL was assessed as a secondary endpoint using EORTC QLQ-C30 and BN20 at baseline (following locoregional therapy but before PCI or observation) and at 6 and 12 months (mos) follow-up. D was defined compared to baseline using the reliable change index method and correlated with overall survival and the cumulative incidence of brain and distant metastases using the Cox proportional hazards and Fine and Gray’s proportional hazards models, respectively. Covariates included age, gender, race, partner status, education, Zubrod performance score, histology, PCI use, and PCI dose. Results: 552 (91%) of the 604 eligible patients accrued to RTOG 0212 and RTOG 0214 had baseline QOL assessments and were included in this pooled analysis. Compliance with QOL assessments (66% at 6 mos and 54% at 12 mos) did not differ between RTOG 0212 and 0214. After adjusting for baseline QOL score and covariates, D in global health status/QOL at 6 and 12 mos, fatigue at 6 and 12 months, and cognitive functioning at 12 months was associated with worse overall survival, compared to no deterioration/improvement (ND) (Table). D in global health status/QOL (1.82, 1.28-2.59, p=0.0009) and fatigue (1.61, 1.15-2.27, p=0.006) at 6 months was also associated with increased risk of distant metastasis. Conclusions: Longitudinal deterioration in global health status/QOL, fatigue and cognitive functioning at 6 and 12 months after definitive treatment for LD-SCLC or LA-NSCLC is potentially an early surrogate marker for poor overall survival. Global Health Status/QOL Fatigue Cognitive functioning 6 mos 12 mos 6 mos 12 mos 12 mos D ND D ND D ND D ND D ND Median survival (mos) 21.4 37.2 30.0 38.6 27.4 33.0 33.0 42.7 28.5 49.0 Adjusted hazard ratio 2.41 2.22 1.71 1.87 1.88 95% confidence interval 1.70-3.43 1.39-3.56 1.20-2.43 1.15-3.04 1.18-3.00 P <0.0001 0.0009 0.003 0.01 0.008
- 1 November 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 78  (3) , S36-S37
Report of Quality Research in Radiation Oncology (QRRO) Survey for Lung Cancer Patients Treated in the USA between 2006 and 2007
- 1 November 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 78  (3) , S36-S37
Report of Quality Research in Radiation Oncology (QRRO) Survey for Lung Cancer Patients Treated in the USA between 2006 and 2007
- 1 November 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75  (3) , S129-S130
Factors Associated with Patterns of Practice for Elective Nodal Irradiation in Non-small Cell Lung Cancer Patients among US Radiation Oncologists
- 1 November 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75  (3) , S129-S130
Factors Associated with Patterns of Practice for Elective Nodal Irradiation in Non-small Cell Lung Cancer Patients among US Radiation Oncologists
- 1 November 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75  (3) , S34
Secondary Endpoints of a Phase II Randomized Trial (RTOG 0212): Impact of Different Total Doses and Schedules of Prophylactic Cranial Irradiation on Chronic Neurotoxicity and Quality of Life for Patients with Limited Disease Small-cell Lung Cancer
- 1 November 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75  (3) , S34
Secondary Endpoints of a Phase II Randomized Trial (RTOG 0212): Impact of Different Total Doses and Schedules of Prophylactic Cranial Irradiation on Chronic Neurotoxicity and Quality of Life for Patients with Limited Disease Small-cell Lung Cancer
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (15) , 7597
Phase II trial of cisplatin (C), etoposide (E), and radiation (RT) followed by gemcitabine (G) versus G and docetaxel (D) in stage III A/B unresectable non-small cell lung cancer (NSCLC)
7597 Background: SWOG 9504 demonstrated highly promising survival rates for D consolidation after E + C and radiation therapy in pts with locally advanced (LA) NSCLC. However, a recent phase III HOG trial suggested no benefit from single-agent D consolidation compared with observation alone (Hanna ASCO 2007 #7512). The current study was developed to assess the feasibility and efficacy of consolidation with either G alone or G + D after the same chemoradiation schedule as SWOG 9504. Methods: The treatment schema included concurrent C 50 mg/m² Day 1, 8 + E 50 mg/m² Day 1–5 for two 28-day cycles + RT 61–62 Gy over 7 weeks after which pts were randomized to consolidation with either G 1000 mg/m² Day 1, 8 (Arm A) or G 1000 mg/m² Day 1, 8 + D 75 mg/m² Day 1 (Arm B) every 21 days for 3 cycles. Eighty-three pts were registered; 64 were randomized to consolidation. Results: See Table. Conclusions: G or G+D following chemoradiation in LA-NSCLC is well tolerated. Preliminary data indicates that consolidation with G+D resulted in prolonged of PFS time with non-overlapping 95% CIs compared with G alone. The doublet, as expected, resulted in more toxicity, particularly myelosuppression and fatigue. Table Characteristics/Results Induction Arm A Arm B No. of available pts 83 32 32 Median age 59.0 59.5 59.5 Male gender, n 66 27 26 ECOG Performance Status, n – – – PS 0 32 11 13 PS 1 51 21 19 No. of pts assessed for safety, Consolidation – 32 32 Neutropenia, Grade 3/4 – 22%/6% 28%/28% Febrile Neutropenia, Grade 3/4 0%/0% 0%/6% Thrombocytopenia, Grade 3/4 6%/0% 19%/0% Anemia, Grade 3/4 3%/0% 13%/6% Dyspnea, Grade 3/4 – 3%/0% 6%/6% Pneumononitis, Grade 3/4 0%/0% 0%/0% Fatigue, Grade 3/4 6%/0% 16%/0% Alopecia, Grade 2 3% 3% Esophagitis, Grade 3/4 0%/0% 0%/0% No of Cycles of Consolidation – – – One 6% 6% Two 3% 25% Three 91% 69% Response to Chemoradiation – – – No. assessed 83 32 32 CR 0% 6% 9% PR 45% 69% 72% SD 22% 25% 3% PD 4% 0% 0 Unknown 30% 0% 13% RR – 75% 81% (95% CI) – (57, 89) (64, 93) No. events for PFS – 26 10 Median PFS, months 8.3 m 24.3 m (95% CI) (5.4, 9.9) (10.6, NE) Number for survival – 32 32 Mean follow-up for survival, months 24.0 19.6 No. events for survival 15 7 Median survival, months 20.1 m NR (95% CI) (13.0, NR) (21.3, NR) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Eli Lilly and Company Eli Lilly and Company Eli Lilly and Company Eli Lilly and Company
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (15) , 7597
Phase II trial of cisplatin (C), etoposide (E), and radiation (RT) followed by gemcitabine (G) versus G and docetaxel (D) in stage III A/B unresectable non-small cell lung cancer (NSCLC)
7597 Background: SWOG 9504 demonstrated highly promising survival rates for D consolidation after E + C and radiation therapy in pts with locally advanced (LA) NSCLC. However, a recent phase III HOG trial suggested no benefit from single-agent D consolidation compared with observation alone (Hanna ASCO 2007 #7512). The current study was developed to assess the feasibility and efficacy of consolidation with either G alone or G + D after the same chemoradiation schedule as SWOG 9504. Methods: The treatment schema included concurrent C 50 mg/m² Day 1, 8 + E 50 mg/m² Day 1–5 for two 28-day cycles + RT 61–62 Gy over 7 weeks after which pts were randomized to consolidation with either G 1000 mg/m² Day 1, 8 (Arm A) or G 1000 mg/m² Day 1, 8 + D 75 mg/m² Day 1 (Arm B) every 21 days for 3 cycles. Eighty-three pts were registered; 64 were randomized to consolidation. Results: See Table. Conclusions: G or G+D following chemoradiation in LA-NSCLC is well tolerated. Preliminary data indicates that consolidation with G+D resulted in prolonged of PFS time with non-overlapping 95% CIs compared with G alone. The doublet, as expected, resulted in more toxicity, particularly myelosuppression and fatigue. Table Characteristics/Results Induction Arm A Arm B No. of available pts 83 32 32 Median age 59.0 59.5 59.5 Male gender, n 66 27 26 ECOG Performance Status, n – – – PS 0 32 11 13 PS 1 51 21 19 No. of pts assessed for safety, Consolidation – 32 32 Neutropenia, Grade 3/4 – 22%/6% 28%/28% Febrile Neutropenia, Grade 3/4 0%/0% 0%/6% Thrombocytopenia, Grade 3/4 6%/0% 19%/0% Anemia, Grade 3/4 3%/0% 13%/6% Dyspnea, Grade 3/4 – 3%/0% 6%/6% Pneumononitis, Grade 3/4 0%/0% 0%/0% Fatigue, Grade 3/4 6%/0% 16%/0% Alopecia, Grade 2 3% 3% Esophagitis, Grade 3/4 0%/0% 0%/0% No of Cycles of Consolidation – – – One 6% 6% Two 3% 25% Three 91% 69% Response to Chemoradiation – – – No. assessed 83 32 32 CR 0% 6% 9% PR 45% 69% 72% SD 22% 25% 3% PD 4% 0% 0 Unknown 30% 0% 13% RR – 75% 81% (95% CI) – (57, 89) (64, 93) No. events for PFS – 26 10 Median PFS, months 8.3 m 24.3 m (95% CI) (5.4, 9.9) (10.6, NE) Number for survival – 32 32 Mean follow-up for survival, months 24.0 19.6 No. events for survival 15 7 Median survival, months 20.1 m NR (95% CI) (13.0, NR) (21.3, NR) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Eli Lilly and Company Eli Lilly and Company Eli Lilly and Company Eli Lilly and Company
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23  (16) , 6073
Breast cancer patients have better outcomes than prostate cancer patients for palliation of painful bone metastases: Results of RTOG 97–14
6073 Background: It is unclear whether there are gender-based differences in pain response and survival after palliative external beam radiotherapy (XRT) for painful bone metastases from breast or prostate cancers. Methods: RTOG and NCCTG conducted a randomized, prospective phase III study of XRT for patients with breast or prostate cancer and painful bone metastases (Brief Pain Index (BPI) worst pain score of ≥5 out of 10). Patients were randomized to 8 Gy in a single fraction vs. 30 Gy in 10 fractions, stratified by number of painful sites, weight bearing site, worst pain score and bisphosphonate usage. Results of the primary study are reported elsewhere; XRT was very effective, providing pain relief in 66% of patients. At 3 months follow-up, there was no difference between the two treatment arms, regardless of stratification. Results: In this gender-based analysis, there were 453 women with breast cancer and 445 men with prostate cancer; median age was 58 and 71 years, respectively. Stratification variables were balanced other than more women received bisphosphonates (46% vs 8% of men). Pain relief was evaluated at 3 months using the BPI. For breast and prostate cancer, complete response was seen in 17% and 16% and partial response in 54% and 43% for an overall response rate of 71% and 59% (p=0.0034) Median survival on the 30 Gy arm for women was 11.6 months compared to 7.3 months for men and median survival on the 8 Gy arm for women was 12.5 months compared to 7.9 months for men. Separate multivariate analyses of the 30 Gy arm and 8 Gy arm, showed that women with breast cancer had statistically significantly longer survival compared to men with prostate cancer (30Gy: HR 1.78, p-value <0.0001; 8Gy: HR 1.75, p-value < 0.0001), after adjusting for age (which was not significant) and KPS. Conclusions: Women with bone metastases from breast cancer experience better outcomes in terms of pain control and survival compared to men with prostate cancer with bone mets treated with palliative radiotherapy. Further consideration should be given to tailoring treatment by gender. Acknowledgment: This trial was supported by NCI grants RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23  (16) , 6073
Breast cancer patients have better outcomes than prostate cancer patients for palliation of painful bone metastases: Results of RTOG 97–14
6073 Background: It is unclear whether there are gender-based differences in pain response and survival after palliative external beam radiotherapy (XRT) for painful bone metastases from breast or prostate cancers. Methods: RTOG and NCCTG conducted a randomized, prospective phase III study of XRT for patients with breast or prostate cancer and painful bone metastases (Brief Pain Index (BPI) worst pain score of ≥5 out of 10). Patients were randomized to 8 Gy in a single fraction vs. 30 Gy in 10 fractions, stratified by number of painful sites, weight bearing site, worst pain score and bisphosphonate usage. Results of the primary study are reported elsewhere; XRT was very effective, providing pain relief in 66% of patients. At 3 months follow-up, there was no difference between the two treatment arms, regardless of stratification. Results: In this gender-based analysis, there were 453 women with breast cancer and 445 men with prostate cancer; median age was 58 and 71 years, respectively. Stratification variables were balanced other than more women received bisphosphonates (46% vs 8% of men). Pain relief was evaluated at 3 months using the BPI. For breast and prostate cancer, complete response was seen in 17% and 16% and partial response in 54% and 43% for an overall response rate of 71% and 59% (p=0.0034) Median survival on the 30 Gy arm for women was 11.6 months compared to 7.3 months for men and median survival on the 8 Gy arm for women was 12.5 months compared to 7.9 months for men. Separate multivariate analyses of the 30 Gy arm and 8 Gy arm, showed that women with breast cancer had statistically significantly longer survival compared to men with prostate cancer (30Gy: HR 1.78, p-value <0.0001; 8Gy: HR 1.75, p-value < 0.0001), after adjusting for age (which was not significant) and KPS. Conclusions: Women with bone metastases from breast cancer experience better outcomes in terms of pain control and survival compared to men with prostate cancer with bone mets treated with palliative radiotherapy. Further consideration should be given to tailoring treatment by gender. Acknowledgment: This trial was supported by NCI grants RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22  (14_suppl) , 6106
Practice type & race influence enrollment onto clinical oncology trials: A Patterns of Care Study analysis
6106 Background: The purpose of this study was to identify key factors influencing accrual to clinical oncology trials.Methods: Patterns of Care Study (PCS) surveys from sites studied between 1992–94 and 1996–99 (prostate cancer [1149 patients], breast cancer [1080 patients], esophageal cancer [818 patients]) were analyzed. PCS is an NCI-funded national survey of randomly selected radiation (RT) institutions in the U.S. Patients with non-metastatic disease, who received RT as definitive or adjuvant therapy, were randomly selected. To determine national estimates, the sample size was weighted by the relative contribution of each institution and patients within each institution. Accordingly, 3,047 patient records were reviewed by trained research associates; the weighted sample size was 132,890. The following factors (age, gender, race, type of insurance and practice type of treating institution [academic or not]) were studied by univariate and multivariate (MVA) analyses.Results: Only 2.7% of all patients were accrued to clinical oncology protocols, consistent with national estimates. On MVA, practice type (p=0.009) and race (p=0.012) were significant predictors of accrual. On univariate analysis, 9.4% of patients treated with RT at an academic practice were accrued vs. 1.7% at non-academic sites (p=0.011). Yet, the vast majority (87%) of all patients were seen at non-academic sites. White patients enrolled onto studies more than African Americans (2.8% vs. 0.8%, p=0.024). Younger age demonstrated a trend towards increased enrollment (3.5% for <70 yrs vs. 1.5% for ≥70 yrs, p=0.058). However, gender and type of insurance were not predictive. A trend towards increased accrual over time was observed (1.5% from '92-'94 vs. 4.2% from '96-'99, p=0.058).Conclusions: Practice type and race significantly influence accrual onto clinical oncology trials. To enhance enrollment, increased communication & education regarding protocols is essential, particularly focused on physicians in non-academic settings and minority patients. Supported by NCI grant CA 65435. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22  (14_suppl) , 6106
Practice type & race influence enrollment onto clinical oncology trials: A Patterns of Care Study analysis
6106 Background: The purpose of this study was to identify key factors influencing accrual to clinical oncology trials.Methods: Patterns of Care Study (PCS) surveys from sites studied between 1992–94 and 1996–99 (prostate cancer [1149 patients], breast cancer [1080 patients], esophageal cancer [818 patients]) were analyzed. PCS is an NCI-funded national survey of randomly selected radiation (RT) institutions in the U.S. Patients with non-metastatic disease, who received RT as definitive or adjuvant therapy, were randomly selected. To determine national estimates, the sample size was weighted by the relative contribution of each institution and patients within each institution. Accordingly, 3,047 patient records were reviewed by trained research associates; the weighted sample size was 132,890. The following factors (age, gender, race, type of insurance and practice type of treating institution [academic or not]) were studied by univariate and multivariate (MVA) analyses.Results: Only 2.7% of all patients were accrued to clinical oncology protocols, consistent with national estimates. On MVA, practice type (p=0.009) and race (p=0.012) were significant predictors of accrual. On univariate analysis, 9.4% of patients treated with RT at an academic practice were accrued vs. 1.7% at non-academic sites (p=0.011). Yet, the vast majority (87%) of all patients were seen at non-academic sites. White patients enrolled onto studies more than African Americans (2.8% vs. 0.8%, p=0.024). Younger age demonstrated a trend towards increased enrollment (3.5% for <70 yrs vs. 1.5% for ≥70 yrs, p=0.058). However, gender and type of insurance were not predictive. A trend towards increased accrual over time was observed (1.5% from '92-'94 vs. 4.2% from '96-'99, p=0.058).Conclusions: Practice type and race significantly influence accrual onto clinical oncology trials. To enhance enrollment, increased communication & education regarding protocols is essential, particularly focused on physicians in non-academic settings and minority patients. Supported by NCI grant CA 65435. No significant financial relationships to disclose.